JP2009515819A5 - - Google Patents

Download PDF

Info

Publication number
JP2009515819A5
JP2009515819A5 JP2008534618A JP2008534618A JP2009515819A5 JP 2009515819 A5 JP2009515819 A5 JP 2009515819A5 JP 2008534618 A JP2008534618 A JP 2008534618A JP 2008534618 A JP2008534618 A JP 2008534618A JP 2009515819 A5 JP2009515819 A5 JP 2009515819A5
Authority
JP
Japan
Prior art keywords
scfv
blood
brain
receptor
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008534618A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009515819A (ja
JP5941607B2 (ja
Filing date
Publication date
Priority claimed from US11/245,710 external-priority patent/US8053569B2/en
Application filed filed Critical
Publication of JP2009515819A publication Critical patent/JP2009515819A/ja
Publication of JP2009515819A5 publication Critical patent/JP2009515819A5/ja
Application granted granted Critical
Publication of JP5941607B2 publication Critical patent/JP5941607B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2008534618A 2005-10-07 2006-09-28 血液脳関門輸送用融合タンパク質 Expired - Fee Related JP5941607B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11/245,710 US8053569B2 (en) 2005-10-07 2005-10-07 Nucleic acids encoding and methods of producing fusion proteins
US11/245,710 2005-10-07
US11/245,546 US8142781B2 (en) 2005-10-07 2005-10-07 Fusion proteins for blood-brain barrier delivery
US11/245,546 2005-10-07
PCT/US2006/038587 WO2007044323A2 (en) 2005-10-07 2006-09-28 Fusion proteins for blood-brain barrier delivery

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014116085A Division JP6320179B2 (ja) 2005-10-07 2014-06-04 血液脳関門輸送用融合タンパク質

Publications (3)

Publication Number Publication Date
JP2009515819A JP2009515819A (ja) 2009-04-16
JP2009515819A5 true JP2009515819A5 (cg-RX-API-DMAC7.html) 2009-11-12
JP5941607B2 JP5941607B2 (ja) 2016-06-29

Family

ID=37943316

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008534618A Expired - Fee Related JP5941607B2 (ja) 2005-10-07 2006-09-28 血液脳関門輸送用融合タンパク質
JP2014116085A Expired - Fee Related JP6320179B2 (ja) 2005-10-07 2014-06-04 血液脳関門輸送用融合タンパク質
JP2016100640A Expired - Fee Related JP6283711B2 (ja) 2005-10-07 2016-05-19 血液脳関門輸送用融合タンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014116085A Expired - Fee Related JP6320179B2 (ja) 2005-10-07 2014-06-04 血液脳関門輸送用融合タンパク質
JP2016100640A Expired - Fee Related JP6283711B2 (ja) 2005-10-07 2016-05-19 血液脳関門輸送用融合タンパク質

Country Status (6)

Country Link
US (2) US8053569B2 (cg-RX-API-DMAC7.html)
EP (2) EP1945259A4 (cg-RX-API-DMAC7.html)
JP (3) JP5941607B2 (cg-RX-API-DMAC7.html)
AU (1) AU2006302589A1 (cg-RX-API-DMAC7.html)
CA (1) CA2625293C (cg-RX-API-DMAC7.html)
WO (1) WO2007044323A2 (cg-RX-API-DMAC7.html)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
ATE512674T1 (de) 2003-01-06 2011-07-15 Angiochem Inc Angiopep-1, verwandte verbindungen, und deren verwnedungen
US7485706B2 (en) * 2003-07-30 2009-02-03 The Board Of Trustees Of The Leland Stanford Junior University Neurodegenerative protein aggregation inhibition methods and compounds
PL2233156T3 (pl) 2005-07-15 2013-09-30 Angiochem Inc Zastosowanie polipeptydów aprotyninowych jako nośników w koniugatach farmaceutycznych
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US7981417B2 (en) * 2006-06-07 2011-07-19 Wisconsin Alumni Research Foundation Blood-brain barrier targeting anti-bodies
AU2007285763B2 (en) * 2006-08-18 2011-12-15 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
WO2008100560A2 (en) * 2007-02-14 2008-08-21 University Of Southern California Estrogen receptor modulators, associated pharmaceutical compositions and methods of use
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US20100197012A1 (en) * 2007-06-05 2010-08-05 National Tsing Hua University Application of RNA Interference Targeting dhfr Gene, to Cell for Producing Secretory Protein
CA3184105A1 (en) * 2007-07-27 2009-02-05 Armagen Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
CN102026667B (zh) 2008-04-18 2014-06-25 安吉奥开米公司 紫杉醇、紫杉醇类似物或紫杉醇结合物的药物组合物及相关制备方法和用途
WO2010043047A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
US8828925B2 (en) 2008-10-15 2014-09-09 Angiochem Inc. Etoposide and doxorubicin conjugates for drug delivery
WO2010063122A1 (en) 2008-12-05 2010-06-10 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
EP2373789A4 (en) 2008-12-17 2012-08-29 Angiochem Inc MEMBRANTYP-1 MATRIX METALLOPROTEINASE INHIBITORS AND THEIR USE
WO2010108048A2 (en) * 2009-03-18 2010-09-23 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
PT2417156E (pt) 2009-04-07 2015-04-29 Roche Glycart Ag Anticorpos trivalentes, biespecíficos
RU2011146654A (ru) 2009-04-20 2013-05-27 Ангиокем Инк. Способы лечения рака яичников с применением конъюгированного средства
CN103819564A (zh) * 2009-06-11 2014-05-28 安吉奥开米公司 用于将gdnf和bdnf递送至中枢神经系统的融合蛋白
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
WO2011000095A1 (en) 2009-07-02 2011-01-06 Angiochem Inc. Multimeric peptide conjugates and uses thereof
EP2722055A1 (en) 2009-08-17 2014-04-23 Tracon Pharmaceuticals, Inc. Combination therapy with antibodies and anti-VEGF agents for the treatment of cancer
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
JP2013507131A (ja) 2009-10-09 2013-03-04 アーメイゲン・テクノロジーズ・インコーポレイテッド Cnsにおけるイズロン酸2−スルファターゼ活性を増加させるための方法および組成物
AU2010306940A1 (en) 2009-10-12 2012-06-07 Smith, Larry Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
CA2800744C (en) * 2010-05-27 2018-09-04 Centocor Ortho Biotech Inc. Insulin-like growth factor 1 receptor binding peptides
WO2012021818A2 (en) * 2010-08-13 2012-02-16 Georgetown University Ggf2 and methods of use
CN103443125B (zh) 2010-11-30 2019-05-03 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9783601B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
JP5768147B2 (ja) 2011-02-28 2015-08-26 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 一価抗原結合タンパク質
WO2012116926A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Antigen binding proteins
US10227387B2 (en) * 2011-05-18 2019-03-12 Children's Hospital Medical Center Targeted delivery of proteins across the blood-brain barrier
DK2758076T3 (en) * 2011-09-24 2019-04-01 Csl Behring Gmbh COMBINATION THERAPY USING IMMUNOGLOBULIN AND C1 INHIBITOR
US8486399B2 (en) 2011-12-02 2013-07-16 Armagen Technologies, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
WO2013177062A2 (en) 2012-05-21 2013-11-28 Genentech, Inc. Methods for improving safety of blood-brain barrier transport
US9421245B2 (en) * 2012-06-25 2016-08-23 The Brigham And Women's Hospital, Inc. Targeted therapeutics
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
CN104781276A (zh) 2012-08-14 2015-07-15 安吉奥开米公司 肽-树枝状聚合物结合物及其用途
JO3462B1 (ar) 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
CA2904357C (en) 2013-03-15 2020-09-22 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
SG11201509566RA (en) 2013-05-20 2015-12-30 Genentech Inc Anti-transferrin receptor antibodies and methods of use
US10906981B2 (en) 2013-07-19 2021-02-02 The Regents Of The University Of California Compositions and methods related to structures that cross the blood brain barrier
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
EP3083977B1 (en) 2013-12-20 2018-02-28 F. Hoffmann-La Roche AG Improved recombinant polypeptide production methods
WO2015091130A1 (en) * 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Method for improving the recombinant production of soluble fusion polypeptides
PL3092251T3 (pl) * 2014-01-06 2021-08-02 F. Hoffmann-La Roche Ag Jednowartościowe moduły transportera wahadłowego przez barierę krew-mózg
CA2961917A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
AU2015346444A1 (en) 2014-11-12 2017-05-04 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
EP3221361B1 (en) 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
JP6779876B2 (ja) 2014-11-19 2020-11-04 ジェネンテック, インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用方法
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
EP3307326B9 (en) 2015-06-15 2021-02-24 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
CA2990785C (en) 2015-06-24 2024-11-12 Jcr Pharmaceuticals Co., Ltd. ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER
AU2016282334B2 (en) 2015-06-24 2022-07-21 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
HK1247933A1 (en) * 2015-06-24 2018-10-05 Jcr Pharmaceuticals Co., Ltd. Fusion protein containing bdnf
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MX2018003822A (es) 2015-10-02 2018-06-22 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
US11752315B1 (en) 2016-10-07 2023-09-12 Carlos A. Hakim Method of treating normal pressure hydrocephalus
CN110621774A (zh) * 2016-10-14 2019-12-27 儿童医疗中心有限公司 用于治疗中枢神经系统疾病和病症的组合物和方法
TWI833178B (zh) 2016-12-26 2024-02-21 日商Jcr製藥股份有限公司 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
TWI791006B (zh) 2016-12-26 2023-02-01 日商Jcr製藥股份有限公司 包含bdnf之融合蛋白質
CA3050690A1 (en) 2017-01-17 2018-07-26 Dana-Farber Cancer Institute, Inc. Compositions and methods for diagnosing and treating peroxisomal diseases
CN108467428A (zh) * 2018-03-26 2018-08-31 江苏中新医药有限公司 一种清除rhNGF中N端截短及异常变异体的方法
DK3774859T3 (da) * 2018-04-11 2024-05-27 Salubris Biotherapeutics Inc Sammensætninger af rekombinante fusionsproteiner af human neuregulin-1 (nrg-1) og fremgangsmåder til anvendelse deraf
JP7532338B2 (ja) * 2018-08-07 2024-08-13 アーマジェン・インコーポレイテッド ヘキソサミニダーゼa、酸スフィンゴミエリナーゼおよびパルミトイル-タンパク質チオエステラーゼ1のcnsにおける活性を増加させるための方法および組成物
WO2020142587A1 (en) * 2019-01-03 2020-07-09 The Board Of Trustees Of The University Of Illinois Method and kit for treating a neurodegenerative disease
US11634501B2 (en) 2019-07-19 2023-04-25 Oncoresponse, Inc. Immunomodulatory antibodies and methods of use thereof
CN114729356A (zh) 2019-08-14 2022-07-08 科迪亚克生物科学公司 靶向stat6的细胞外囊泡-aso构建体
CN114729327A (zh) 2019-08-14 2022-07-08 科迪亚克生物科学公司 具有stat3反义寡核苷酸的细胞外囊泡
EP4013878A1 (en) 2019-08-14 2022-06-22 Codiak BioSciences, Inc. Extracellular vesicle-aso constructs targeting cebp/beta
CA3147365A1 (en) 2019-08-14 2021-02-18 Joanne LIM Extracellular vesicle-nlrp3 antagonist
EP4013872A1 (en) 2019-08-14 2022-06-22 Codiak BioSciences, Inc. Extracellular vesicles with antisense oligonucleotides targeting kras
EP4034247A1 (en) 2019-09-25 2022-08-03 Codiak BioSciences, Inc. Sting agonist comprising exosomes for treating neuroimmunological disorders
WO2021184021A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting pmp22
WO2021184020A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Methods of treating neuroinflammation
US20230220068A1 (en) 2020-06-05 2023-07-13 Codiak Biosciences, Inc. Anti-transferrin extracellular vesicles
CA3128035A1 (en) 2020-08-13 2022-02-13 Bioasis Technologies, Inc. Combination therapies for delivery across the blood brain barrier
JP2022108271A (ja) 2021-01-12 2022-07-25 Jcrファーマ株式会社 リガンドと生理活性を有する蛋白質の融合蛋白質をコードする遺伝子が組み込まれた核酸分子
JP2024512236A (ja) 2021-02-17 2024-03-19 ロンザ セールス アーゲー 細胞外ベシクル-nlrp3アンタゴニスト
CN112851759B (zh) * 2021-02-23 2022-12-27 李婧炜 噬菌体展示技术筛选可穿越血-脑脊液屏障的多肽
TW202330591A (zh) 2021-11-19 2023-08-01 日商Jcr製藥股份有限公司 人類運鐵蛋白受體親和性肽
EP4455290A4 (en) 2021-12-28 2025-11-26 Japan Chem Res Fusion protein of an anti-transferrin receptor antibody and a bioactive protein for safe gene therapy
JP2024056666A (ja) * 2022-10-11 2024-04-23 Jcrファーマ株式会社 血清アルブミンと生理活性を有する蛋白質との融合蛋白質
TW202436352A (zh) 2023-02-07 2024-09-16 日商Jcr製藥股份有限公司 人類運鐵蛋白受體親和性肽
EP4762080A1 (en) * 2023-08-14 2026-06-24 The Bionics Institute of Australia A fusion protein

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5229500A (en) 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
US5180820A (en) 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
US5154924A (en) * 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
TW279133B (cg-RX-API-DMAC7.html) 1990-12-13 1996-06-21 Elan Med Tech
US6060069A (en) 1991-05-20 2000-05-09 Dura Pharmaceuticals, Inc. Pulmonary delivery of pharmaceuticals
US6287792B1 (en) 1991-06-17 2001-09-11 The Regents Of The University Of California Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
WO1993006116A1 (en) 1991-09-20 1993-04-01 Syntex-Synergen Neuroscience Joint Venture Glial derived neurotrophic factor
JPH06228199A (ja) * 1992-11-27 1994-08-16 Takeda Chem Ind Ltd 血液脳関門通過可能なペプチド結合体
US5997501A (en) 1993-11-18 1999-12-07 Elan Corporation, Plc Intradermal drug delivery device
PT706799E (pt) * 1994-09-16 2002-05-31 Merck Patent Gmbh Imunoconjugados ii
US5656284A (en) 1995-04-24 1997-08-12 Balkin; Michael S. Oral transmucosal delivery tablet and method of making it
CN1137680C (zh) 1995-09-19 2004-02-11 藤泽药品工业株式会社 气雾剂组合物
US5837231A (en) 1996-06-27 1998-11-17 Regents Of The University Of Minnesota GM-CSF administration for the treatment and prevention of recurrence of brain tumors
WO1999000150A2 (en) * 1997-06-27 1999-01-07 Regents Of The University Of California Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
US6482923B1 (en) * 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
US6016800A (en) 1997-10-24 2000-01-25 Century; Theodore J. Intrapulmonary aerosolizer
US6905686B1 (en) * 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
DK1037687T3 (da) 1997-12-11 2009-01-26 Alza Corp Anordning til at forbedre et middels transdermale strömning
US6348210B1 (en) 1998-11-13 2002-02-19 Alza Corporation Methods for transdermal drug administration
US6375975B1 (en) 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
US6284262B1 (en) 1999-01-26 2001-09-04 Virgil A. Place Compact dosage unit for buccal administration of a pharmacologically active agent
US7309687B1 (en) 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US6372250B1 (en) 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
US6696274B2 (en) 2000-05-03 2004-02-24 Supratek Pharma, Inc. Ligand for enhancing oral and CNS delivery of biological agents
US7078376B1 (en) 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
AU2002246580A1 (en) 2000-12-04 2002-07-24 The Regents Of The University Of California Antisense imaging of gene expression of the brain in vivo
WO2002062832A2 (en) 2001-02-06 2002-08-15 Merck Patent Gmbh Modified human brain-derived neutrophic factor (bdnf) with reduced immunogenicity
CA2450073C (en) * 2001-07-25 2017-08-29 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
JP4219152B2 (ja) * 2002-10-31 2009-02-04 ヤマハマリン株式会社 船舶推進機におけるオイル交換時期警報装置
US6850492B2 (en) * 2002-11-22 2005-02-01 Nokia Corporation Method and system for enabling a route and flow table update in a distributed routing platform
US20040102369A1 (en) 2002-11-27 2004-05-27 The Regents Of The University Of California Transport of basic fibroblast growth factor across the blood brain barrier
US20050142141A1 (en) 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US7294704B2 (en) * 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
EP1548031A1 (en) 2003-12-22 2005-06-29 Dubai Genetics FZ-LLC Nature-identical erythropoietin
US20060222668A1 (en) * 2005-04-01 2006-10-05 Wellspring Pharmaceutical Corporation Stannsoporfin compositions, drug products and methods of manufacture
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8124095B2 (en) 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
WO2008065372A2 (en) 2006-11-28 2008-06-05 Nautilus Biotech, S.A. Modified erythropoietin polypeptides and uses thereof for treatment
JP6083219B2 (ja) * 2012-12-06 2017-02-22 富士通セミコンダクター株式会社 プラズマフラッドガン及びイオン注入装置

Similar Documents

Publication Publication Date Title
Courade et al. Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau
Bélanger et al. Single-domain antibodies as therapeutic and imaging agents for the treatment of CNS diseases
US9387260B2 (en) VHH antibodies used as peptide vectors for delivering a substance of interest
JP2025026843A5 (cg-RX-API-DMAC7.html)
JP2018524001A5 (cg-RX-API-DMAC7.html)
CN112236452A (zh) 检测和治疗阿尔茨海默氏病的基于抗体的方法
HRP20180516T1 (hr) Humanizirana protutijela specifična za protofibrilni oblik amiloidnog-beta peptida
JP2010539921A5 (cg-RX-API-DMAC7.html)
JP2010506596A5 (cg-RX-API-DMAC7.html)
UA99701C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с лигандом-1 запрограммированной гибели клеток (pd-l1)
JP2014503198A5 (cg-RX-API-DMAC7.html)
JP2012100677A5 (cg-RX-API-DMAC7.html)
JP2010531144A5 (cg-RX-API-DMAC7.html)
JP2015509097A5 (cg-RX-API-DMAC7.html)
JP2013529070A5 (cg-RX-API-DMAC7.html)
JP2018530331A5 (cg-RX-API-DMAC7.html)
US11098096B2 (en) Alzheimer Aβ peptide binding polypeptide
Geerts et al. Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology model
JP2018518940A5 (cg-RX-API-DMAC7.html)
Gao et al. Single domain antibody-based vectors in the delivery of biologics across the blood–brain barrier: A review
Li et al. Swedish mutant APP-based BACE1 binding site peptide reduces APP β-cleavage and cerebral Aβ levels in Alzheimer’s mice
JP2023515708A5 (cg-RX-API-DMAC7.html)
Ferrantelli et al. Engineered extracellular vesicles/exosomes as a new tool against neurodegenerative diseases
Niazi et al. Engineered antibodies to improve efficacy against neurodegenerative disorders
JP2024544936A5 (cg-RX-API-DMAC7.html)